Trevi Therapeutics Announces Second Quarter 2020 Financial Results and Business Update
August 13, 2020 16:05 ET
|
Trevi Therapeutics
Announced Positive Outcome of Sample Size Re-Estimation Analysis for PRISM Trial Strong Enrollment in PRISM Trial After Lifting of COVID-19 Restrictions Announces $14 Million Term Loan - Cash...
Trevi Therapeutics to Report Q2 2020 Financial Results on August 13
August 06, 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Trevi Therapeutics to Present at BTIG Virtual Biotechnology Conference
August 05, 2020 07:30 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Trevi Therapeutics Announces Positive Outcome of the Sample Size Re-Estimation Analysis in PRISM Trial for Severe Pruritus in Patients With Prurigo Nodularis
July 13, 2020 07:30 ET
|
Trevi Therapeutics
Independent Data Monitoring Committee Recommends Continuation of PRISM Trial with Expansion to 360 Subjects per the Adaptive Design Enrollment Expected to be Complete by Third Quarter 2021 ...